Arianna Johnson is a reporter on the Forbes news desk who covers explainers and trends, with a frequent focus on health and science. She joined Forbes in 2022 and works in Texas. Johnson has covered prominent weight loss drugs like Ozempic and Wegovy, the health effects of the artificial sweetener aspartame and the impacts of the Covid vaccines.
Friday, a week after giving Pfizer and Moderna the OK on their shots, though all drugmakers say their shots will be available within the coming days ahead of the fall and winter respiratory virus surge.the JN.1 COVID-19 variant, which was the dominant strain circulating in the U.S. earlier this year but now makes up less than 1% of cases.The FDA in June asked vaccine makers to create shots that target the coronavirus’ JN.
Novavax told Forbes its vaccines will be available in “thousands of locations” as soon as the FDA’s Center for Biologics Evaluation and Research releases the vaccine batches.its vaccine"will begin shipping immediately and be available in pharmacies, hospitals, and clinics across the U.S. beginning in the coming days.”
The FDA said it granted accelerated use authorization to Moderna and Pfizer’s updated jabs on August 22 to “more closely target currently circulating variants and provide better protection against serious consequences of COVID-19,” the agency said in itsWe’re launching text message alerts so you'll always know the biggest stories shaping the day’s headlines.
Moderna Pfizer Moderna Covid Vaccine Pfizer Covid Vaccine Updated Covid Vaccine New Covid Vaccine Novavax Novavax Vaccine Novavax Covid Vaccine
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA approves new blood test for colon cancer screening: ‘Early detection is critical’The FDA has approved a new blood test for colorectal cancer. Shield, made by Guardant Health, is the first approved blood test that is considered a primary screening option for the disease.
Read more »
FDA Approves First Engineered Cell Therapy for a Solid TumorThe afami-cel approval marks the first for an engineered T-cell receptor therapy targeting a solid tumor; the therapy was approved for adults with unresectable or metastatic synovial sarcoma.
Read more »
FDA Approves First Targeted Therapy for Gliomas With IDH MutationsThe approval marks the first for a targeted therapy for grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation.
Read more »
Endometrial cancer patients see new hope as FDA approves 'transforming' immunotherapy drugThe FDA has approved a new drug for some adult patients with endometrial cancer. Jemperli (dostarlimably) — made by U.K. company GSK — is intended for primary advanced or recurrent disease.
Read more »
FDA Approves First Nalmefene Auto-Injector for Opioid OverdoseZurnai, from Purdue, is the first nalmefene hydrochloride auto-injector for known or suspected opioid overdose in people aged 12 years and older.
Read more »
FDA Approves Lymphir for R/R Cutaneous T-Cell LymphomaThe agent, which has returned to the US market in a reformulated version, is indicated for adults with relapsed or refractory stage 1-3 disease.
Read more »